Angelo Pirozzi, Research Fellow at Mayo Clinic, shared on X: .
“92 Circulating-immuno-oncology-related proteins in patients with metastatic PDAC (Pancreatic Ductal Adenocarcinoma) from the CheckPAC trial who responded to radiotherapy +nivolumab ± ipilimumab.
High FASLG (FAS ligand) and Gal-1 lead to higher PFS (progression-free survival)
Circulating immune-related proteins might predict the efficacy of ICIs (Immune Checkpoint Inhibitors).”
Proceed to the article.
Source: Angelo Pirozzi/X